Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients

26 Jun 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Background. There has been an annual rise in the incidence of primary membranous nephropathy (PMN), a common pathological type of nephrotic syndrome (NS). Obinutuzumab is a humanised, glycosylated, type II anti-CD20 monoclonal antibody.
Characterised by its enhanced B-cell depletion capability compared with rituximab (RTX), obinutuzumab has demonstrated promising efficacy in the treatment of membranous nephropathy. Objective. This study aimed to investigate the efficacy and safety of obinutuzumab in treating various subtypes of PMN.Methods.
A total of 94 PMN patients with NS were enrolled in this study. Based on their treatment history before receiving obinutuzumab, the patients were categorised into the Initial therapy group (group A, n=32), the Refractory group (group B, n=32), and the Remedial therapy group (group C, n=30). The efficacy and safety of obinutuzumab treatment after a 24-month follow-up period were observed and analysed in each group.

Clinical Editorial

Summary

Frontiers in Immunology published a clinical update in Infectious Disease on 26 Jun 2026.

The item focuses on Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients.

Review the original article for the full source wording and details.